Proteasome Inhibition as a Cancer Type-Specific Off-Target Effect of Everolimus in Cancer Cells

Area of Science:

• Molecular Biology
• Cancer Research
• Pharmacology

Background:

• Everolimus is an mTORC1 inhibitor with potential effects on proteasome activity, similar to bortezomib.
• Understanding the comprehensive mechanism of action of everolimus is crucial for its therapeutic application.

Purpose of the Study:

• To investigate the secondary targets of everolimus, specifically its effect on proteasome activity.
• To elucidate the mechanism of action of everolimus in various cancer cell lines using advanced proteomic techniques.

Main Methods:

• Ultrafast expression proteomics was utilized to analyze proteomes.
• Cell viability and proteasome activity assays were performed.
• In silico modeling was employed to predict drug-target interactions.

Main Results:

• Everolimus demonstrated 20S proteasome inhibition in lung (A549) and colon (HCT116) cancer cells.
• No significant proteasome inhibition by everolimus was observed in breast cancer cells (MCF-7).
• An in silico model suggested an allosteric mechanism for everolimus-induced proteasome inhibition.

Conclusions:

• Everolimus exhibits cancer cell-specific proteasome inhibition, impacting its therapeutic potential.
• The findings provide insights into the off-target effects of everolimus and suggest novel therapeutic strategies.